Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAPDH | P04406 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182368 | 0.92 | ACHE (0.45) | LMNAMAOBACHEMAPTALDH1A1 | |
| SCHEMBL12413215 | 0.87 | LMNA (0.45) | LMNAMAOBACHEMAPTALDH1A1 | |
| SCHEMBL2180009 | 0.81 | CA2 (0.44) | LMNAACHEMAPTALDH1A1CYP3A4 | |
| SCHEMBL12413283 | 0.75 | LMNA (0.45) | LMNAMAOBMAPTALDH1A1CYP3A4 | |
| SCHEMBL12413264 | 0.74 | LMNA (0.43) | LMNAMAOBMAPTALDH1A1GAPDH | |
| SCHEMBL12413374 | 0.73 | LMNA (0.40) | LMNAMAOBMAPTALDH1A1GAA | |
| SCHEMBL12413367 | 0.73 | PTGS2 (0.46) | LMNAMAOBGAAPTGS2CA2 | |
| SCHEMBL12413209 | 0.73 | LMNA (0.42) | LMNAMAOBMAPTALDH1A1GAA | |
| SCHEMBL12413295 | 0.73 | LMNA (0.42) | LMNAMAOBMAPTALDH1A1GAPDH | |
| SCHEMBL12413254 | 0.73 | LMNA (0.42) | LMNAMAOBMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NFE2L2, PTGS2, PTGES2 | LMNA 2234/4885MAOB 580/4885ACHE 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.